Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zavegepant - Pfizer

X
Drug Profile

Zavegepant - Pfizer

Alternative Names: BHV 3500; BMS-742413; BMS-742413-03; Vazegepant; Vazegepant - Pfizer; Zavegepant hydrochloride; ZAVZPRET

Latest Information Update: 05 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Pfizer
  • Class Anti-infectives; Antiallergics; Antimigraines; Indazoles; Piperazines; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II/III COVID-19 respiratory infection
  • Phase I Allergic asthma

Most Recent Events

  • 13 Apr 2024 Adverse events data from a phase II/III trial in Migraine presented at the 76th Annual Meeting of the American Academy of Neurology (AAN-2024)
  • 13 Apr 2024 Drug interactions data from a preclinical studies presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
  • 21 Mar 2024 Biohaven Pharmaceuticals terminates a phase II/III trial for Migraine (Prevention, In adults, In the elderly) in March 2021 (PO, Capsule) as per a strategic decision for the adjusted development plan for the drug (NCT04804033)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top